The altered expression level of TUBB3 was observed in many human cancer cells, and its aberrant expression was found to be associated with enhanced chemoresistance and poor prognosis in NSCLC, ovarian cancer, gastric cancer, breast cancer, and uterine serous carcinoma (43–46). This evidence concerns the gene TUBB3 and non-small cell lung carcinoma.